GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Fennec Pharmaceuticals
Fennec Pharmaceuticals is a biopharmaceutical company focused on a single drug to prevent hearing loss in children undergoing chemotherapy. Its stock price reflects its success in securing approval and commercialization of this niche but important drug.
Share prices of companies in the market segment - General oncology therapy
Fennec Pharmaceuticals (FENC) is a specialty pharmaceutical company focused on developing Pedmark, a drug for the prevention of hearing loss in children undergoing platinum-based chemotherapy. We classify this drug as "General Oncotherapy." The chart below shows the dynamics of the maintenance therapy segment in oncology.
Broad Market Index - GURU.Markets
Fennec Pharmaceuticals is a pharmaceutical company focused on preventing hearing loss in children undergoing chemotherapy. Its unique niche makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Fennec compares to the overall market dynamics.
Change in the price of a company, segment, and market as a whole per day
FENC - Daily change in the company's share price Fennec Pharmaceuticals
Shares of Fennec, a biopharmaceutical company, are highly volatile. Change_co measures market reaction to the commercial success of its drug for protecting children's hearing during chemotherapy. This metric is an important component of formulas on System.GURU.Markets that evaluate niche pharmaceutical companies.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Fennec Pharmaceuticals Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing this to FENC, whose success hinges on a single hearing loss drug, helps to understand its high concentration risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Fennec is a pharmaceutical company specializing in drugs to treat the side effects of chemotherapy in children. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Fennec's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Fennec Pharmaceuticals
Fennec Pharmaceuticals' year-to-date performance tells the story of its drug's launch to prevent hearing loss in children undergoing chemotherapy. Its 12-month market cap reflects the success of commercializing this niche but critically important product, the culmination of years of development and approval efforts.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Fennec Pharmaceuticals Inc. is a commercial biopharmaceutical company focused on treating chemotherapy-induced hearing loss in children. This chart shows how its success in commercializing this unique and important drug is impacting its performance in the oncology sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Fennec is a biopharmaceutical company whose stock performance is driven by the commercialization of its products and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Fennec Pharmaceuticals
Fennec, a pharmaceutical company, is dependent on its product cycle for its market capitalization. The monthly fluctuations on the chart reflect the commercial launch of its lead drug for preventing hearing loss in children undergoing chemotherapy, the success of which is crucial to its future.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Fennec Pharmaceuticals specializes in developing drugs to prevent hearing loss in children receiving platinum-based chemotherapy. This is a highly specialized but very important market. The chart below reflects the overall sentiment in the oncology therapeutics sector, where Fennec addresses treatment side effects.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Fennec Pharmaceuticals is a company focused on a single drug to prevent hearing loss in children undergoing chemotherapy. Its success depends entirely on the commercialization of this product. Share price performance is driven by sales reports and is independent of overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Fennec Pharmaceuticals
Shares of Fennec Pharmaceuticals, which focuses on preventing chemotherapy-related hearing loss in children, are news-sensitive. Weekly price movements depend on sales data for its sole approved drug and regulatory announcements. The chart below shows how short-term events impact the valuation of a single-product company.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
How typical are Fennec Pharmaceuticals' performance trends for the pharmaceutical sector? This chart compares the weekly stock price movements of a company with one approved drug to the industry average. This helps us understand whether its reaction to sales and competitive news is more acute than that of large, diversified pharmaceutical companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Fennec Pharmaceuticals specializes in a drug to prevent hearing loss in children undergoing chemotherapy. This chart compares its weekly performance to the market. It helps us understand how its narrow focus and dependence on the success of a single product make its shares volatile and uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
FENC - Market capitalization of the company Fennec Pharmaceuticals
Fennec Pharmaceuticals' market capitalization is based on a single product: a drug to prevent hearing loss in children undergoing chemotherapy. The company's value depends entirely on the commercial success of this niche but important drug. The chart illustrates how the market values the potential of this single asset.
FENC - Share of the company's market capitalization Fennec Pharmaceuticals within the market segment - General oncology therapy
Fennec Pharmaceuticals is building market share by developing and commercializing the first and only treatment to prevent hearing loss caused by cisplatin-based chemotherapy in children.
Market capitalization of the market segment - General oncology therapy
Here's a chart showing the market capitalization of pharmaceutical companies focused on ultra-rare (orphan) diseases. Fennec Pharmaceuticals is a leader in its niche. The graph shows how the market values drugs that address unique and vital medical problems.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's a visualization of the market value of a company fighting chemotherapy side effects. Fennec Pharmaceuticals' market cap is based on the valuation of its hearing protection drug for children undergoing cancer treatment. The chart illustrates how this highly specialized drug could carve out an important niche in the global oncology field.
Book value capitalization of the company, segment and market as a whole
FENC - Book value capitalization of the company Fennec Pharmaceuticals
Fennec Pharmaceuticals' book value represents its intellectual capital. The chart below reflects the valuation of its rights to PEDMARK®, a drug designed to prevent hearing loss in children undergoing chemotherapy. The dynamics show how the company monetizes its core and highly specialized asset.
FENC - Share of the company's book capitalization Fennec Pharmaceuticals within the market segment - General oncology therapy
Fennec Pharmaceuticals' tangible assets include its R&D infrastructure and manufacturing contracts for the development of drugs aimed at reducing the side effects of chemotherapy. The chart shows its share of this highly specialized pharmaceutical company, focused on improving the quality of life of cancer patients.
Market segment balance sheet capitalization - General oncology therapy
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, Fennec, with its focus on a single niche drug, appears "light." The company doesn't strive to build gigantic factories; its model is based on the development and commercialization of a specific product, making it capital-efficient.
Book value of all companies included in the broad market index - GURU.Markets
Fennec Pharmaceuticals is a company focused on a single drug that prevents hearing loss in children undergoing chemotherapy. Its assets are the rights to this drug and its commercial infrastructure. The company's balance sheet is the value of solving a single, yet very important and real medical problem.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Fennec Pharmaceuticals
Fennec's balance sheet consists of its cash and the rights to a single drug. Market capitalization is an estimate of the commercial potential of this niche drug. The MvsBCap_Co chart shows how the market values the sales prospects of a single product relative to the company's assets.
Market to book capitalization ratio in a market segment - General oncology therapy
Fennec Pharmaceuticals specializes in developing drugs to prevent hearing loss in children undergoing chemotherapy. The chart shows the market valuation of its niche but important drug. The valuation is highly dependent on commercial success and the expansion of its indications.
Market to book capitalization ratio for the market as a whole
Fennec Pharmaceuticals specializes in developing drugs to prevent hearing loss in children undergoing chemotherapy. It's a highly specialized company solving an important medical problem. This chart helps assess how the market perceives biotech companies focused on niche but important indications.
Debts of the company, segment and market as a whole
FENC - Company debts Fennec Pharmaceuticals
For Fennec Pharmaceuticals, a company focused on a single drug to prevent chemotherapy-induced hearing loss in children, debt is a tool for commercialization. This chart shows how the company raises capital to bring its product to market after receiving approval. Here, debt is the final push to turn years of research into revenue.
Market segment debts - General oncology therapy
Fennec Pharmaceuticals is a company focused on developing a drug to prevent hearing loss in children undergoing chemotherapy. Working in the niche field of pediatric oncology has its own specifics and risks. This chart shows how a small pharmaceutical company is funding its path to commercialization of a vital but niche product.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Fennec Pharmaceuticals
Fennec Pharmaceuticals specializes in drugs to prevent hearing loss in children undergoing chemotherapy. This chart shows how the company finances its operations. For a pharmaceutical company with a narrow focus, debt is a significant risk, as its financial future depends entirely on the commercial success of one key product.
Market segment debt to market segment book capitalization - General oncology therapy
Fennec Pharmaceuticals is a company focused on developing a drug to prevent hearing loss in children undergoing chemotherapy. This is a highly specialized niche. The chart shows how the company's debt load, which is preparing for commercialization, compares to the overall market capitalization of the oncology sector.
Debt to book value of all companies in the market
Fennec Pharmaceuticals (FENC) specializes in drugs to prevent hearing loss in children undergoing chemotherapy. It's a niche pharmaceutical company. This chart shows the debt burden of the entire economy. It's interesting to see what financial strategy (debt or equity) a niche player chooses after receiving approval for its product.
P/E of the company, segment and market as a whole
P/E - Fennec Pharmaceuticals
This chart shows the valuation of Fennec Pharmaceuticals, a company whose main product is designed to prevent hearing loss in children undergoing chemotherapy. The P/E is dependent on the success of the commercial launch of this niche but important drug. Its dynamics will be determined by the pace of its adoption in oncology practice.
P/E of the market segment - General oncology therapy
This chart shows the average P/E for niche pharmaceutical companies. For Fennec, with its hearing loss prevention drug, this is an important benchmark. Comparing its P/E to the sector average will help understand how investors evaluate the commercial potential of its highly specialized product.
P/E of the market as a whole
Fennec Pharmaceuticals is a specialty pharmaceutical company focused on developing a treatment to prevent hearing loss in children undergoing platinum-based chemotherapy. The company is addressing a significant unmet medical need. This chart helps assess how the market views companies with a single key product.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Fennec Pharmaceuticals
Fennec Pharmaceuticals is a company focused on one goal: preventing hearing loss in children receiving platinum-based chemotherapy. Their drug, Pedmark, is designed to address this problem. This graph reflects the expected commercial success of this niche but important drug. The valuation depends on its sales volume and acceptance by the medical community.
%20P%2FE%20Fennec%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Fennec-Pharmaceuticals&v=1772638365258 "Chart of the company's future (projected) P/E Fennec Pharmaceuticals")
Future (projected) P/E of the market segment - General oncology therapy
Fennec Pharmaceuticals specializes in drugs to prevent hearing loss in children undergoing chemotherapy. This chart compares the company's future profitability expectations with the pharmaceutical industry average. It reflects the market's confidence in the commercial success of their niche but important drug, PEDMARK.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772638365289 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Fennec Pharmaceuticals specializes in drugs to prevent hearing loss in children undergoing chemotherapy. This is a niche but important market. The company's success depends on the commercialization of its single product. This market expectations chart provides investors with a backdrop against which to evaluate the potential of such niche projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772638365307 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Fennec Pharmaceuticals
Fennec Pharmaceuticals is a company focused on developing a single drug, Pedmark, designed to prevent hearing loss in children receiving platinum-based chemotherapy. Its financial success is entirely dependent on the commercial launch and sales of this highly targeted drug.
Profit of companies in the market segment - General oncology therapy
Fennec Pharmaceuticals specializes in drugs to prevent hearing loss in children undergoing chemotherapy. It's a highly specialized but important niche. This chart illustrates how small biotech companies, by solving specific medical problems, contribute to the overall profitability of the pharmaceutical industry by identifying underserved markets.
Overall market profit
Fennec Pharmaceuticals is a company focused on preventing hearing loss in children undergoing chemotherapy. This is a highly specialized market with an unmet medical need. Fennec's success depends on the commercialization of its single drug and is unrelated to the general economic cycles that shape this graph.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Fennec Pharmaceuticals
Fennec Pharmaceuticals specializes in drugs to prevent hearing loss caused by platinum-based chemotherapy in children. The future revenue projections shown in this chart depend on the commercial success of its only approved drug, Pedmark. The speed of its acceptance by oncologists will determine whether these projections are met.
%20profit%20of%20the%20company%20Fennec%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Fennec-Pharmaceuticals&v=1772638365531 "Graph of future (projected) profit of the company Fennec Pharmaceuticals")
Future (predicted) profit of companies in the market segment - General oncology therapy
Fennec Pharmaceuticals is developing PEDMARK, a drug for preventing hearing loss in children undergoing chemotherapy. This chart shows the revenue forecast for the overall general oncology sector. It reflects expected demand for maintenance therapy in oncology, which is key to assessing the market potential of Fennec's niche product.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772638365555 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Fennec Pharmaceuticals specializes in drugs to prevent hearing loss in children undergoing chemotherapy. This is a very niche market. The company's success depends on regulatory approval and physician acceptance of its drug. Economic cycles, as reflected here, have a lesser impact on the company, but they can impact healthcare budgets.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772638365564 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Fennec Pharmaceuticals
Fennec Pharmaceuticals is a company focused on developing a single product, Pedmark, designed to prevent hearing loss in children receiving platinum-based chemotherapy. This chart shows how investors assess the commercial potential of this highly specialized but important drug following regulatory approval.
P/S market segment - General oncology therapy
Fennec Pharmaceuticals is a specialty pharmaceutical company focused on developing Pedmark, a drug for preventing hearing loss caused by platinum-based chemotherapy in children with cancer. This chart shows the average market valuation for this niche and important drug, helping to understand how the market views the potential of this important drug.
P/S of the market as a whole
Fennec Pharmaceuticals is a company focused on developing a drug to prevent hearing loss in children undergoing platinum-based chemotherapy. This is a narrow but important niche with an unmet need. This overall market valuation chart helps understand the premium investors are willing to pay for the potentially high but risky revenue potential of this niche biotech.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Fennec Pharmaceuticals
Fennec Pharmaceuticals specializes in drugs to prevent hearing loss in children undergoing chemotherapy. Future revenue depends on the successful launch of its product. This chart reflects the market's assessment of the commercial potential of this niche but important drug.
%20P%2FS%20Fennec%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Fennec-Pharmaceuticals&v=1772638365601 "The graph of the company's future (projected) P/S Fennec Pharmaceuticals")
Future (projected) P/S of the market segment - General oncology therapy
Fennec Pharmaceuticals specializes in developing pediatric oncology drugs. This chart compares market expectations for its future revenue with those of other oncology companies. This estimate reflects investor sentiment about its key drug, Pedmark, designed to prevent hearing loss in children undergoing chemotherapy.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772638365615 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Fennec Pharmaceuticals is a company focused on preventing hearing loss in children undergoing chemotherapy. This is a very specific but important niche. The overall market optimism, reflected in this chart, creates a favorable environment in which investors are willing to fund companies solving rare but significant medical problems.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772638365642 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Fennec Pharmaceuticals
Fennec Pharmaceuticals is a company focused on developing a drug to prevent hearing loss in children undergoing chemotherapy. The company's revenue is generated from sales of this single commercialized product. This chart shows the market acceptance of this important drug, which addresses a serious medical problem.
Sales of companies in the market segment - General oncology therapy
Fennec Pharmaceuticals is a company focused on developing a single product, Pedmark, designed to prevent hearing loss in children undergoing platinum-based chemotherapy. Once approved, all company revenue will be generated from sales of this drug. This graph illustrates the potential of the orphan drug market, where a successful product could capture the entire niche.
Overall market sales
Fennec Pharmaceuticals specializes in drugs to prevent hearing loss in children undergoing chemotherapy. This is a highly specialized market, and the company's success depends on the commercialization of its single product. The overall economic situation, as illustrated here, impacts hospital budgets and the speed of implementation of new supportive therapies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Fennec Pharmaceuticals
Fennec Pharmaceuticals is a company focused on a single drug, Pedmark, designed to prevent hearing loss in children receiving platinum-based chemotherapy. This chart shows analysts' expectations for the pace of adoption of this drug in pediatric oncology following its regulatory approval.
%20sales%20of%20the%20company%20Fennec%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Fennec-Pharmaceuticals&v=1772638365747 "Schedule of future (projected) sales of the company Fennec Pharmaceuticals")
Future (projected) sales of companies in the market segment - General oncology therapy
Fennec Pharmaceuticals specializes in developing drugs to prevent chemotherapy-induced hearing loss in children. The data in this chart shows the outlook for the oncology therapeutics sector. This allows one to assess how focusing on a narrow but important niche could ensure the company's commercial success should its key drug be approved.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772638365760 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Fennec Pharmaceuticals specializes in a drug to prevent hearing loss in children undergoing chemotherapy. This schedule, reflecting healthcare costs, is important to the company. Stable funding for cancer centers and the willingness of insurance systems to cover maintenance therapy are key factors for the commercial success of Fennec.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772638365810 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Fennec Pharmaceuticals
Fennec Pharmaceuticals is a specialty pharmaceutical company whose primary goal is to commercialize a drug to prevent hearing loss in children undergoing chemotherapy. This chart shows the company's financial path from development to commercialization of a niche but vital product, as well as its ability to generate profits.
Market segment marginality - General oncology therapy
Fennec Pharmaceuticals specializes in PEDMARK, a drug designed to prevent hearing loss in children undergoing chemotherapy. Focusing on a single product for a rare but important indication is their strategy. This chart shows how this narrow focus impacts the company's operational efficiency after approval and sales.
Market marginality as a whole
Fennec Pharmaceuticals is a company focused on a single product that prevents hearing loss in children undergoing chemotherapy. Unlike the general picture of profitability, their story is one of successfully bringing a drug to market that addresses a very specific and unmet need. Their profitability depends on the successful commercialization of this unique product.
Employees in the company, segment and market as a whole
Number of employees in the company Fennec Pharmaceuticals
Fennec Pharmaceuticals is a specialty pharmaceutical company focused on treating rare pediatric oncologies. This graph shows the team working on commercializing its first product. The growth in staff reflects the shift from R&D to building a commercial infrastructure.
Share of the company's employees Fennec Pharmaceuticals within the market segment - General oncology therapy
Fennec Pharmaceuticals specializes in developing drugs to prevent chemotherapy-induced hearing loss in children. This chart shows its market share in the niche field of maintenance therapy in oncology. It reflects the company's focus and the team's dedication to solving this important medical problem, improving the quality of life for young patients.
Number of employees in the market segment - General oncology therapy
Fennec Pharmaceuticals specializes in developing drugs to prevent hearing loss caused by platinum-based chemotherapy in children. This chart shows the company's workforce in the specialty pharmaceuticals business. The dynamics reflect the company's long and challenging journey to bring a drug to market to address an unmet medical need in pediatric oncology.
Number of employees in the market as a whole
Fennec Pharmaceuticals is a company focused on developing a single drug, PEDMARK, designed to prevent hearing loss in children undergoing chemotherapy. This is a highly specialized and important niche. This chart illustrates the overall impact, where even small biopharmaceutical companies play a significant role by solving critical medical problems and recruiting exceptional talent.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Fennec Pharmaceuticals (FENC)
Fennec Pharmaceuticals Inc. specializes in drugs to prevent hearing loss in children undergoing chemotherapy. It's a highly specialized business, where value is determined by a single key product. This chart shows a high cost per employee, as managing the development and commercialization of such a drug requires a small but highly focused team.
%20of%20the%20company%20Fennec%20Pharmaceuticals%20(FENC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Fennec-Pharmaceuticals-FENC&v=1772638365956 "Chart of market capitalization per employee (in thousands of dollars) of the company Fennec Pharmaceuticals (FENC)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Fennec Pharmaceuticals specializes in drugs to prevent hearing loss in children undergoing chemotherapy. This is a very narrow and socially significant niche. The chart shows how the market perceives the commercial potential of its single key product based on its small, focused team, which distinguishes it from large pharmaceutical companies.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772638365958 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Fennec Pharmaceuticals specializes in drugs to prevent hearing loss in children undergoing chemotherapy. This is a very niche but important market. This chart shows how the market views the potential of their approved drug, Pedmark. The cost per employee reflects the value of solving a rare but serious medical problem.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772638365973 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Fennec Pharmaceuticals (FENC)
Fennec Pharmaceuticals (FENC) is a company focused on a single product—Pedmark, a treatment for preventing hearing loss in children undergoing chemotherapy. This chart shows how successfully the company is commercializing this ultra-niche drug. It measures how much revenue is generated by a small team focused on this single asset.
%20Chart%20Fennec%20Pharmaceuticals%20(FENC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Fennec-Pharmaceuticals-FENC&v=1772638365989 "Company Profit Per Employee (in thousands of dollars) Chart Fennec Pharmaceuticals (FENC)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Fennec Pharmaceuticals is focused on a single product: Pedmark, a drug for preventing chemotherapy-induced hearing loss in children. This chart shows the benchmark for employee profitability in the pharmaceutical industry. It's important for assessing how effectively the Fennec team is commercializing its single product.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772638366003 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Fennec Pharmaceuticals is a small pharmaceutical company focused on a single commercial product, PEDMARK, which prevents hearing loss in children undergoing chemotherapy. It's a very niche, yet important, drug. This chart shows how effectively their small commercial team can sell this highly specialized, high-margin product to cancer centers.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772638366019 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Fennec Pharmaceuticals (FENC)
Fennec Pharmaceuticals is a company focused on preventing hearing loss in children undergoing chemotherapy. This graph shows the company's path from development to commercialization. Revenue per employee growth will reflect the company's success in bringing its highly specialized yet life-saving drug to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Fennec-Pharmaceuticals-FENC&v=1772638366030 "Sales chart per company employee Fennec Pharmaceuticals (FENC)")
Sales per employee in the market segment - General oncology therapy
Fennec Pharma (FENC) is a pharmaceutical company focused on a single product, Pedmark, which prevents hearing loss in children undergoing cisplatin chemotherapy. This chart shows how much revenue each employee generates from sales of this niche but important drug. It's an indicator of their commercial performance.
Sales per employee for the market as a whole
Fennec Pharmaceuticals is a single-product company. Their drug, Pedmark, is approved to prevent hearing loss in children undergoing chemotherapy. This is a niche but important market. This chart shows how successfully their small, focused team is commercializing this single drug, generating revenue in its narrow but important medical segment.
Short shares by company, segment and market as a whole
Shares shorted by company Fennec Pharmaceuticals (FENC)
Fennec Pharmaceuticals is a company focused on a single drug (Pedmark) designed to prevent hearing loss in children undergoing chemotherapy. This chart shows bearish bets. Shorts may be driven by doubts about the drug's commercial success. The market is very small, and the company has encountered manufacturing issues that delayed FDA approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Fennec-Pharmaceuticals-FENC&v=1772638366141 "Short Shares Chart for the Company Fennec Pharmaceuticals (FENC)")
Shares shorted by market segment - General oncology therapy
Fennec Pharmaceuticals (FENC) is a company focused on a single product (Pedmark), designed to prevent hearing loss in children undergoing platinum-based chemotherapy. This chart shows bets against the specialty pharmaceutical sector. The rising bets against the industry may reflect investor concerns about the slow commercialization of this niche drug.
Shares shorted by the overall market
Fennec Pharmaceuticals (FENC) is a company with a single product approved to prevent chemotherapy-related hearing loss in children. It's a highly specialized business. This general fear chart isn't as significant for FENC as it is for other biotechs, as it has a product. However, general panic still dampens appetite for small-cap stocks.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Fennec Pharmaceuticals (FENC)
Fennec Pharmaceuticals is a biotech with one approved drug (Pedmark) to prevent chemotherapy-related hearing loss in children. This chart measures how investors view the commercial launch of this niche drug. It shows when the stock is overbought due to expectations or oversold due to weak sales.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Fennec-Pharmaceuticals-FENC&v=1772638366314 "RSI 14 indicator chart for the company's stock Fennec Pharmaceuticals (FENC)")
RSI 14 Market Segment - General oncology therapy
Fennec Pharmaceuticals is a pharmaceutical company specializing in oncology. Their lead product (Pedmark) is approved for the prevention of hearing loss in children undergoing cisplatin-based chemotherapy. This chart measures the overall momentum in the oncology biotech sector. It helps differentiate FENC's performance from the broader industry trend.
RSI 14 for the overall market
Fennec Pharmaceuticals, a biotech company, depends on this schedule. To fund expensive clinical trials, it requires a constant influx of capital. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like FENC are forced to struggle to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast FENC (Fennec Pharmaceuticals)
Fennec Pharmaceuticals is focused on PEDMARK, a drug designed to prevent hearing loss in children receiving platinum-based chemotherapy. This chart shows the average target price. Analysts' forecasts are based on the pace of commercialization of this highly specialized but important drug.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-FENC-Fennec-Pharmaceuticals&v=1772638366433 "A chart showing analyst consensus forecasts for the expected stock price. FENC (Fennec Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price FENC (Fennec Pharmaceuticals)
Fennec (FENC) is a biopharmaceutical company whose lead drug (Pedmark) is approved to prevent hearing loss in children receiving cisplatin-based chemotherapy. This chart shows their commercialization assessment. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their unique drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-FENC-Fennec-Pharmaceuticals&v=1772638366458 "A chart showing the difference between the consensus forecast and the actual stock price. FENC (Fennec Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Fennec Pharmaceuticals (FENC) is a company whose only product, Pedmark, is approved for the prevention of hearing loss in children receiving platinum-based chemotherapy. This chart shows general expectations for the oncology sector, reflecting whether experts believe in the commercial success of this niche "protective" drug.
Analysts' consensus forecast for the overall market share price
Fennec Pharmaceuticals is a company focused on a single product (Pedmark), designed to prevent hearing loss in children receiving platinum-based chemotherapy. This chart shows overall market sentiment. For Fennec, whose success depends on the commercialization of this niche but important drug, overall optimism is important, but sales and regulatory approval news are more important.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Fennec Pharmaceuticals
Fennec Pharmaceuticals is a single-bet biotech company. Their sole product (Pedmark) is a drug designed to prevent hearing loss in children receiving platinum-based chemotherapy. This chart is a summary indicator of their commercial launch, reflecting their ability to convince oncologists to use their niche but important drug.
AKIMA Market Segment Index - General oncology therapy
Fennec Pharmaceuticals specializes in PEDMARK, a drug designed to prevent hearing loss in children undergoing platinum-based chemotherapy. This chart shows the average index for the oncology sector. It allows one to assess how Fennec's highly specialized business model compares to the industry average.
The AKIM Index for the overall market
Fennec Pharmaceuticals is commercializing the drug Pedmark, which prevents hearing loss in children undergoing chemotherapy. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this niche oncology business stacks up against overall economic trends.
